The company, which provides outsourced sales and marketing, drug distribution and packaging services to healthcare companies, forecast its full-year adjusted profit-per-share to be 4 percent to 6 percent higher compared with 45.9 cents in 2018.

All estimates are on a constant currency basis, the company said.

(The story corrects headline and paragraph 1 to say Ireland's UDG, not Britain's)

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)